Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Phase I to supply clean energy to five facilities, with long-term plans to power 19 hospitals through a 30 MW renewable network
Board approves five-year appointment, subject to shareholder nod through postal ballot
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Subscribe To Our Newsletter & Stay Updated
